Intramuscular Hydroxyprogesterone Caproate and Placenta Previa
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Antepartum hemorrhage is defined as bleeding from or within the female genital tract,
occurring from 24+0 weeks of pregnancy and till delivery of the fetus. Antepartum hemorrhage
occurs in 3-5% of pregnancies and is an important cause of perinatal and maternal morbidity
and mortality worldwide.
Placenta previa is a placenta inserted wholly or in part into the lower segment of the
uterus. It is classified by ultrasound to Placenta previa major degree when the lower edge of
the placenta lies within 2 cm from the internal cervical os and Placenta previa minor degree
if the lower edge of the placenta at lower uterine segment but more than 2 cm from internal
os. Placenta previa is responsible for 0.03% of maternal mortality and 8.1% of perinatal
mortality of 8.1% in the developed world and much more in developing countries.
Many studies in literature proved the positive correlation between the Placenta previa and
preterm uterine contractility and also reported that large proportion of women who have
Placenta previa associated with vaginal bleeding will have subclinical uterine contractions
before the onset of evident vaginal bleeding.
There are many tocolytic agents may have a role in conservative management of Placenta previa
such as magnesium sulfate and β-sympathomimetics .Progesterone is essential for continuation
of pregnancy and helps in maintenance of pregnancy . Delaying delivery may reduce the fetal
morbidity by helping maturity of vital organs. In 2003 Meis et al. in a large randomized
placebo-controlled trial found a significant reduction in recurrent preterm birth before 37
weeks for women who received 17αHP-C versus a control group receiving placebo (36.3% versus
54.9%).